Aytu Biopharma (AYTU) Accounts Payables (2011 - 2026)

Aytu Biopharma (AYTU) has reported Accounts Payables for 15 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Accounts Payables rose 9.74% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 9.74% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, up 2.78% from the prior year.
• Accounts Payables was $13.2 million for Q1 2026 at Aytu Biopharma, down from $14.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.3 million in Q4 2025 and troughed at $10.3 million in Q2 2024.
• A 4-year average of $12.0 million and a median of $12.0 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables fell 23.48% in 2024 and climbed 21.88% in 2025, its largest moves.
• Over 4 years, Accounts Payables stood at $10.5 million in 2023, then gained by 11.71% to $11.7 million in 2024, then climbed by 21.88% to $14.3 million in 2025, then dropped by 7.33% to $13.2 million in 2026.
• The last three Accounts Payables figures came in at $13.2 million (Q1 2026), $14.3 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.